ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
Loading
Research and development spending
3Y CAGR
+71.4%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
5x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $153.35M | +94.1% |
| 2024 | $79.00M | +21.8% |
| 2023 | $64.88M | +113.2% |
| 2022 | $30.43M | +373.0% |
| 2021 | $6.43M | - |